Novartis drug strikes back at bone-marrow disease; Valeant chief pledges $30M to Duke U; Philly judge upholds Topamax verdict;

@FiercePharma: Catch this week's issue of FiercePharmaMarketing here. Issue | Follow @FiercePharma

@TracyStaton: Novartis nabs Merck exec Bruno Strigini to head up oncology business. More | Follow @TracyStaton

@EricPFierce: RT from @FiercePharma: Smells like team spirit: AstraZeneca CEO says Pfizer fight has it pumped to perform. Story | Follow @EricPFierce

@CarlyHFierce: Out with the old, in with the new: Merck, GSK, others put established drugs on the block. News | Follow @CarlyHFierce

@JustinHFierce: #NPPCWPX THE WORLD PORK EXPO HAS A MEDIA ROOM. | Follow @JustinHFierce

> The Novartis ($NVS) blood cancer drug Jakavi did a better job of controlling polycythemia vera, an incurable bone marrow cancer, compared with best available therapy, a study found. Release

> Valeant Pharmaceuticals ($VRX) CEO Michael Pearson committed $30 million in donations to the engineering school at Duke University, his alma mater. Report

> A Philadelphia judge upheld an $11 million verdict against Johnson & Johnson's ($JNJ) Janssen unit in a Topamax liability case. Report

> India's Glenmark Pharmaceuticals threw open the doors on its new antibody manufacturing facility in Switzerland. Release

> Biotech companies fear that a Supreme Court decision in a tech-company case could undermine their method patents. Report

> Price caps in the EU are undercutting generics makers and could ultimately cause companies to pull out of certain markets or cut jobs, a trade group says. Report

Medical Device News

@FierceMedDev: Singapore team designs nanotech glaucoma treatment for sustained release. Story from FierceDrugDelivery | Follow @FierceMedDev

@VarunSaxena2: The EU continues to talk medical device reform. What will the finished regulations look like? More from The National Law Review | Follow @VarunSaxena2

@MichaelGFierce: 'Quadrapeutics' method delivers chemo, nanogold, infrared light and radiation to kill cancer. More from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Learning a second language could help ward off dementia, say researchers @UniofEdinburgh. More | Follow @EmilyWFierce

> GE wins FDA approval for automated breast imaging system . News

> Pixium Vision looks to raise $45M in European IPO. Article

> Former ArthroCare top execs convicted of securities fraud scheme. Article

Biotech News

@FierceBiotech: Trending--Sanofi CEO Viehbacher now calls beloved Boston biotech hub his home. More | Follow @FierceBiotech

@JohnCFierce: No. 1 - $31M; No. 2 - $8M: 2013's 10 best-compensated R&D chiefs in biopharma. Report | Follow @JohnCFierce

@DamianFierce: Science pays: 2013's 10 best-compensated R&D chiefs in biopharma. Feature | Follow @DamianFierce

@EmilyMFierce: Genetically engineered malaria parasite could expedite vaccine development. ICYMI from FierceBiotech Research | Follow @EmilyMFierce

> Biotech boom or no, many startups are staying virtual. Story

> Analyst prods Amgen to join the Big Pharma breakup party. More

> Biotech claims a dubious Alzheimer's 'breakthrough.' Item

> Trevi, Complexa bag $38M in VC cash to hit the gas on R&D. Article

> Shire sweetens its arGEN-X deal with a $20M investment. News

Drug Delivery News

> 'Quadrapeutics' method delivers chemo, nanogold, infrared light and radiation to kill cancer. More

> Singapore team designs nanotech glaucoma treatment for sustained release. Article

> First cheek-bound film for opioid dependence nears PDUFA date. Report

> Investors watch RNA therapy companies for signs of future profits. Item

> FDA approves first nasally delivered gel for 'Low T.' Story

Diagnostics News

> Quest and Memorial Sloan-Kettering team for next-generation gene sequencing. Report

> Five urine biomarkers may offer a new way to spot male infertility. Item

> Provista broadens ASU cancer biomarker licensing deal. More

> NanoString to produce companion test for Celgene's blockbuster cancer drug Revlimid. Article

> Almac at ASCO: Dx spots ovarian cancer patients for whom Roche's Avastin would hurt. Story

Pharma Marketing News

> Pfizer launches next new Lipitor copay program, Medicare and ACA included. Report

> GlaxoSmithKline's Chinese reps demand to be repaid for bribes, FT reports. More

> Novartis, Merck KGaA use digital tracking in MS patients to up their competitive game. Story

> AstraZeneca's Crestor gets a boost from Cigna data-crunching deal. Article

> Pfizer launches next new Lipitor copay program, Medicare and ACA included. More

And Finally... Merck & Co. ($MRK) CEO Kenneth Frazier said the company is proud to be an American, but wants to pay lower taxes just as the companies re-domiciling outside the U.S. do. Report

Suggested Articles

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.